Ellen Lambrix and Adam Coughlin from Bristows' Commercial IP team attended the BioIntegrates conference in London on 16 May 2023. With...

Cell and gene therapies (CGTs) are highly complex and sophisticated technologies with a lot of constituent parts. To bring a product to...

This HFEA consultation, launched on Tuesday, is important not only for IVF clinics, but to all those working in the fields of...

The life sciences industry saw unprecedented levels of activity in 2020 and 2021 in the fight against Covid. In 2022 we saw a different...

Platform technologies, often the core business of a biotech or techbio company, can be extremely valuable assets. Whether it’s a high...

At the start of this year, BioNTech announced a strategic partnership with the UK government to provide up to 10,000 patients with...

Libmeldy® is a treatment for early-onset metachromatic leukodystrophy (MLD), a rare, inherited and otherwise fatal disease that causes...

Last month, Atara Biotherapeutics’ Ebvallo was granted marketing authorisation in the EU - the first off-the-shelf T-cell immunotherapy...

Which is more sensible, sacrificing hundreds of laboratory mice during the development of a therapeutic or using highly advanced model...

UCLB, the commercialisation company of UCL, held a Winter Showcase event on 16 November 2022 to highlight some of their recent successes...

Cell and gene therapies (CGTs) are transforming the way we treat, and even cure, disease. Since the first CAR-T therapy was approved in...

BIA’s TechBio UK Event Bristows had the pleasure of attending TechBio UK 2022 on 13 October. It was a fantastic event held by the...